グライコミクス/グリコバイオロジーの世界市場：製品タイプ別、用途別、技術別、地域別、範囲および予測

グライコミクス/グリコバイオロジーの市場規模と予測

グライコミクス/グリコバイオロジーの市場規模は、2024年に14億3,000万米ドルと評価され、2031年には52億5,000万米ドルに達すると予測され、2024年から2031年までのCAGRは17.60%で成長します。グライコミクス/グリコバイオロジーは分子生物学の一分野であり、タンパク質や脂質に結合した複合糖質である糖鎖を研究し、さまざまな生物学的プロセスにおいて重要な役割を果たします。糖鎖の構造、その形成、関係、および細胞や生物体内での活性を徹底的に調べます。グライコミクス/グリコバイオロジーは、生物学的研究、診断、治療において幅広い応用が可能です。異常な糖鎖パターンは、疾患の進行や重症度と頻繁に対応するため、がん、自己免疫疾患、感染症などの疾患の理解に役立ちます。糖鎖は、病気の診断や予後のバイオマーカーとして、また治療的介入やワクチン開発の標的として使用されます。

グライコミクス/グリコバイオロジーの将来は、個別化医療、精密診断、およびテーラーメイド治療を前進させる可能性を提供します。質量分析やグリコシルマイクロアレイのような糖鎖分析法が進歩すれば、研究者は糖鎖の多様性と機能をより深く探求できます。このトピックは、創薬、バイオマーカー開発、特定の糖鎖プロファイルにカスタマイズされた治療技術の進歩を促進し、最終的には世界のヘルスケア成果の改善につながると予測されます。

世界のグライコミクス/グリコバイオロジー市場力学

主な市場促進要因

生物医学研究の進歩：

特にがん、自己免疫疾患、感染症における糖鎖の役割を理解するための生物医学研究の進歩が、グライコミクス技術の需要を促進しています。診断や治療のために糖鎖バイオマーカーを研究する研究者が増えており、これが市場拡大の原動力となっています。

技術革新：

高分解能質量分析、糖鎖マイクロアレイ、バイオインフォマティクスツールなど、グライコミクス技術の絶え間ない進歩により、糖鎖分析能力が向上しています。これらの技術はグライコミクス研究の効率、精度、スケーラビリティを向上させ、市場の成長を促します。例えば、2024年1月、Bruker Corporationは、糖鎖研究に卓越した分解能を提供する新しいtimsTOF Ultra質量分析計のリリースを発表しました。この装置は1ppm以下の質量精度で糖鎖異性体を検出することができ、グライコミクス技術の大幅な改善となります。

創薬と開発：

グライコミクスは、治療療法のための糖鎖標的の同定に役立つため、医薬品開発において重要です。個別化医療と生物製剤の重視の高まりが、糖鎖に焦点を当てた医薬品開発の需要を支え、業界を前進させています。

ヘルスケア支出の増加：

世界のヘルスケア支出の増加は、グライコミクスのような高度な研究・診断技術への投資を促進します。ヘルスケアプロバイダーや製薬会社は、新しいバイオマーカー、診断法、治療法を生み出すためにグライコミクスに投資しており、市場成長を促進しています。2024年2月、OECD（経済協力開発機構）は、加盟国が2023年にヘルスケアの研究開発予算を平均7.2%増加させ、その大きな割合をグライコミクスのような高度なバイオテクノロジーに投じたとする調査結果を発表しました。

主な課題

糖鎖構造の複雑さ：

糖鎖は構造的に複雑かつ不均一であるため、その研究は困難です。生物間や組織間で糖鎖構造が異なるため、専門的な分析手順が必要となり、費用と時間がかかります。

限られた標準化：

糖鎖分析のための確立された技術や標準物質がないことがハードルとなっています。グリコシル分離手順、分析技術、およびデータの解釈にばらつきがあるため、グライコミクス研究結果の再現性と比較可能性が低下します。

技術的限界：

飛躍的な進歩にもかかわらず、既存のグライコミクス法は感度、分解能、スループットにおいて限界があります。これらの問題に対処し、臨床現場でのグライコミクスの利用を拡大するためには、ハードウェアとバイオインフォマティクスツールの改善が必要です。

高い研究開発コスト：

グライコミクスの研究開発には、特殊な装置、試薬、および有能な人材への多額の投資が必要です。糖鎖分析および技術導入にかかるコストが高いため、特に小規模の研究所やヘルスケア機関では市場参入が制限される可能性があります。

主な動向：

精密医療へのシフト：

病気の診断、予後、治療のために患者固有の糖鎖バイオマーカーを開発する上で、グライコミクスが重要な役割を果たすなど、オーダーメイド医療への傾向が強まっています。この動向は、臨床現場におけるグライコミクス技術の利用を後押ししています。

ビッグデータとバイオインフォマティクスの統合：

バイオインフォマティクスとデータ解析の進歩により、大規模なグライコミクスデータを他のオミックスデータセットと統合することが可能になっています。この統合により、糖鎖構造と機能をより詳細に調べることが可能になり、生物学的経路と疾患プロセスのより深い理解につながります。

糖鎖バイオマーカー応用の拡大：

糖鎖バイオマーカーは、がん、自己免疫疾患、感染症など、さまざまな疾患における診断および予後の価値がますます認識されるようになっています。新規糖鎖バイオマーカーの探索により、臨床研究および診断におけるグライコミクスの利用が拡大しています。

共同研究の取り組み：

学術機関、製薬企業、バイオテクノロジー企業が協力してグライコミクス研究を推進しています。これらの共同研究は、蓄積された専門知識とリソースを活用して糖鎖ベースの診断薬および治療薬の開発を加速し、市場のイノベーションを促進することを目的としています。

目次

第1章 イントロダクション

• 市場の定義
• 市場セグメンテーション
• 調査手法

第2章 エグゼクティブサマリー

• 主な調査結果
• 市場概要
• 市場ハイライト

第3章 市場概要

• 市場規模と成長の可能性
• 市場動向
• 市場促進要因
• 市場抑制要因
• 市場機会
• ポーターのファイブフォース分析

第4章 グライコミクス/グリコバイオロジー市場：製品タイプ別

• 酵素
• 器具
• キット
• 試薬

第5章 グライコミクス/グリコバイオロジー市場：用途別

• 創薬・医薬品開発
• 疾患診断
• その他（個別化医療など）

第6章 グライコミクス/グリコバイオロジー市場：技術別

• クロマトグラフィー
• 質量分析
• 電気泳動
• NMR（核磁気共鳴）

第7章 地域別分析

• 北米
• 米国
• カナダ
• メキシコ
• 欧州
• 英国
• ドイツ
• フランス
• イタリア
• アジア太平洋
• 中国
• 日本
• インド
• オーストラリア
• ラテンアメリカ
• ブラジル
• アルゼンチン
• チリ
• 中東・アフリカ
• 南アフリカ
• サウジアラビア
• アラブ首長国連邦

第8章 市場力学

• 市場促進要因
• 市場抑制要因
• 市場機会
• COVID-19の市場への影響

第9章 競合情勢

• 主要企業
• 市場シェア分析

第10章 企業プロファイル

• Thermo Fisher Scientific
• Danaher Corporation
• Merck KGaA
• Promega Corporation
• Waters Corporation
• Agilent Technologies
• Takara Bio Inc
• Bio-Techne
• Bruker Corporation
• Shimadzu Corporation

第11章 市場の展望と機会

• 新興技術
• 今後の市場動向
• 投資機会

第12章 付録

• 略語リスト
• 出典と参考文献

Glycomics/Glycobiology Market Size And Forecast

Glycomics/Glycobiology Market size was valued at USD 1.43 Billion in 2024 and is projected to reach USD 5.25 Billion by 2031 , growing at a CAGR of 17.60% from 2024 to 2031. Glycomics Glycobiology is a discipline of molecular biology that studies glycans, which are complex carbohydrates linked to proteins and lipids that play important roles in a variety of biological processes. It entails a thorough examination of glycan structures, their formation, relationships, and activities inside cells and organisms. Glycomics Glycobiology offers wide-ranging applications in biological research, diagnostics, and treatments. It is useful in understanding diseases like cancer, autoimmune disorders, and infectious diseases because aberrant glycan patterns frequently correspond with disease progression and severity. Glycans are used as biomarkers in illness diagnosis and prognosis, as well as targets for therapeutic interventions and vaccine development.

The future of glycomics glycobiology provides the potential to advance personalized medicine, precision diagnostics, and tailored therapeutics. Researchers can explore deeper into glycan variety and function as glycan analysis methods like mass spectrometry and glycosyl microarrays progress. This topic is predicted to foster advances in drug discovery, biomarker development, and therapeutic techniques customized to specific glycan profiles, ultimately improving global healthcare outcomes.

Global Glycomics Glycobiology Market Dynamics

The key market dynamics that are shaping the global glycomics glycobiology market include:

Key Market Drivers:

Biomedical Research Advancements:

Advances in biomedical research, notably in understanding the role of glycans in cancer, autoimmune disorders, and infectious diseases, are driving demand for glycomics technologies. Researchers are increasingly studying glycan biomarkers for diagnostics and treatments, which is driving market expansion.

Technological Innovations:

Continuous advances in glycomics technologies, such as high-resolution mass spectrometry, glycan microarrays, and bioinformatics tools, improve glycan analysis capability. These technologies increase efficiency, precision, and scalability in glycomics research, hence encouraging market growth. For instance in January 2024, Bruker Corporation has announced the release of their new timsTOF Ultra mass spectrometer, which provides exceptional resolution for glycan research. The device can detect glycan isomers with a mass accuracy of less than 1 ppm, which is a substantial improvement in glycomics technology.

Drug Discovery and Development:

Glycomics is important in drug development because it helps identify glycan targets for therapeutic therapies. The increased emphasis on personalized medicine and biologics supports demand for glycan-focused medication development, propelling the industry forward.

Rising Healthcare Expenditure:

Increasing global healthcare spending encourages investments in advanced research and diagnostic technologies, such as glycomics. Healthcare providers and pharmaceutical companies are investing in glycomics to create new biomarkers, diagnostics, and therapeutics, driving market growth. In February 2024, the OECD (Organisation for Economic Cooperation and Development) published a study claiming that member nations boosted their healthcare R&D budgets by an average of 7.2% in 2023, with a large share going to sophisticated biotechnologies such as glycomics.

Key Challenges:

Complexity of Glycan Structures:

Glycans are structurally complicated and heterogeneous, making their study difficult. Variations in glycan structures among organisms and tissues necessitate specialized analytical procedures, which can be expensive and time-consuming.

Limited Standardization:

The lack of established techniques and reference materials for glycan analysis creates a hurdle. Variability in glycosyl separation procedures, analytical techniques, and data interpretation reduces the repeatability and comparability of glycomics research findings.

Technological Limitations:

Despite breakthroughs, existing glycomics methods may be limited in sensitivity, resolution, and throughput. Improvements in hardware and bioinformatics tools are required to address these issues and broaden glycomics' use in clinical settings.

High Research and Development Costs:

Research and development in glycomics necessitate large investments in specialized equipment, reagents, and qualified personnel. The high costs involved with glycan analysis and technology adoption may limit market access, especially for smaller research laboratories and healthcare organizations.

Key Trends:

Shift to Precision Medicine:

There is an increasing trend toward customized medicine, with glycomics playing an important role in developing patient-specific glycan biomarkers for illness diagnosis, prognosis, and therapy. This trend is boosting the use of glycomics technology in clinical settings.

Integration of Big Data and Bioinformatics:

Advances in bioinformatics and data analytics are making it possible to integrate large-scale glycomics data with other omics data sets. This integration allows for more thorough investigations of glycan structures and functions, which leads to better understanding of biological pathways and disease processes.

Expansion of Glycan Biomarker Applications:

Glycan biomarkers are increasingly becoming recognized for their diagnostic and prognostic value in a variety of diseases, including cancer, autoimmune disorders, and infectious diseases. The search for novel glycan biomarkers is broadening the use of glycomics in clinical research and diagnosis.

Collaborative research initiatives:

Academic institutions, pharmaceutical corporations, and biotechnology enterprises are working together to advance glycomics research. These collaborations aim to use their pooled expertise and resources to speed the development of glycan-based diagnostics and therapeutics, thereby driving market innovation.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Glycomics Glycobiology Market Regional Analysis

Here is a more detailed regional analysis of the global glycomics glycobiology market:

North America:

North America dominates the worldwide glycomics and glycobiology market, owing to a strong ecosystem of variables. The region has a strong foundation of academic institutions and research centers at the forefront of glycomics research, resulting in a thorough understanding of the subject.

Furthermore, significant investments from both the public and commercial sectors drive innovation and technical progress. A thriving biotechnology and pharmaceutical industry fuels the market, with multiple companies working on glycan-based medicines, diagnostics, and research tools.

Furthermore, a favorable regulatory environment promotes research and development, easing the transition of scientific discoveries into commercial products. These characteristics combine to place North America as the epicenter of glycomics and glycobiology, propelling worldwide market growth and innovation.

Asia Pacific:

Asia Pacific is emerging as a major player in the worldwide glycomics and glycobiology industry. The region is seeing significant investments in the field, driven by rising healthcare costs, an increase in the prevalence of chronic diseases, and a greater emphasis on research and development.

The presence of a big population and a developing middle class with increasing disposable income is driving demand for advanced healthcare solutions, such as glycomics-based diagnostics and therapies.

Furthermore, supportive government efforts and collaborations between academics and industry are promoting innovation and hastening market expansion. While now following North America, Asia Pacific is poised to become a significant player in the global glycomics and glycobiology landscape.

Global Glycomics Glycobiology Market: Segmentation Analysis

The Global Glycomics Glycobiology Market is segmented on the basis of By Product Type, By Application, By Technology and By Geography.

Global Glycomics Glycobiology Market, By Product Type

• Enzymes
• Instruments
• Kits
• Reagents

Based on Product Type, the Global Glycomics Glycobiology Market is segmented into Enzymes, Instruments, Kits, and Reagents. Reagents are dominant because to their critical function in glycan analysis and characterization operations. Kits are expanding the fastest, driven by the need for standardized processes and convenience of use in glycomics research and diagnostics.

Global Glycomics Glycobiology Market, By Application

• Drug Discovery & Development
• Disease Diagnostics
• Personalized Medicine

Based on Application, the Global Glycomics Glycobiology Market is segmented into Drug Discovery & Development, Disease Diagnostics, and personalized Medicine. Drug development & Development dominates, with a growing emphasis on glycan-based medicines and biomarker development. Personalized Medicine is the fastest expanding segment, driven by advances in glycomics technology that enable tailored treatment approaches and diagnostics.

Global Glycomics Glycobiology Market, By Technology

• Chromatography
• Mass Spectrometry
• Electrophoresis
• NMR (Nuclear Magnetic Resonance)

Based on Technology, the Global Glycomics Glycobiology Market is segmented into Chromatography, Mass Spectrometry, Electrophoresis, and NMR (Nuclear Magnetic Resonance). Mass spectrometry emerges as the leading section, owing to its excellent sensitivity and accuracy in glycan analysis. Chromatography is experiencing the most rapid expansion, because to advances in column technology and increased uses in glycomics research and development.

Global Glycomics Glycobiology Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World

Based on the Geography, the Global Glycomics Glycobiology Market are classified into North America, Europe, Asia Pacific, and Rest of the World. North America is the dominant region due to strong research infrastructure and significant investment in biotechnology. Asia Pacific has the quickest growth rate, owing to increased biotech research initiatives, rising healthcare investments, and expanding pharmaceutical industries.

Key Players

• The "Global Glycomics Glycobiology Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
• Thermo Fisher Scientific, Danaher Corporation, Merck KGaA, Promega Corporation, Waters Corporation, Agilent Technologies, Takara Bio, Inc., Bio-Techne, Bruker Corporation, Shimadzu Corporation.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

• Global Glycomics Glycobiology Market: Recent Developments
• In March 2024, Genentech Announced Breakthrough in Glycoengineering Genentech, a Roche Group company, has disclosed a substantial development in Glycoengineering approaches for monoclonal antibodies. Their innovative technology enables precise control of glycosylation patterns, potentially increasing the efficacy and decreasing immunogenicity of therapeutic antibodies. This advancement may lead to more effective treatments for a variety of ailments, including cancer and autoimmune disorders.
• In February 2024, Glycomimetics, a clinical-stage biotechnology company, announced good findings from their Phase 3 trial of uproleselan, a new E-selectin antagonist, in combination with chemotherapy for relapsed/refractory acute myeloid leukemia (AML). The experiment found significant improvements in overall survival and remission rates, underscoring the potential of glycobiology-based cancer treatments.
• In January 2024, Siemens Healthineers has launched a new high-throughput glycan analysis platform for biopharmaceutical quality monitoring. This automated approach allows for rapid and exact characterisation of glycosylation profiles in therapeutic proteins, meeting a crucial requirement in the biopharmaceutical industry for efficient glycoform analysis.
• In December 2023, ProZyme, a glycobiology reagent and tool company, has established a strategic relationship with Thermo Fisher Scientific to create breakthrough glycoanalytical solutions. This collaboration intends to bring together ProZyme's expertise in glycan-specific reagents with Thermo Fisher's analytical instruments, potentially expediting glycomics research and biomarker development.

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Glycomics/Glycobiology Market, By Product Type

• Enzymes
• Instruments
• Kits
• Reagents

5. Glycomics/Glycobiology Market, By Application

• Drug Discovery & Development
• Disease Diagnostics
• Others (such as personalized medicine)

6. Glycomics/Glycobiology Market, By Technology

• Chromatography
• Mass Spectrometry
• Electrophoresis
• NMR (Nuclear Magnetic Resonance)

7. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

8. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

9. Competitive Landscape

• Key Players
• Market Share Analysis

10. Company Profiles

• Thermo Fisher Scientific
• Danaher Corporation
• Merck KGaA
• Promega Corporation
• Waters Corporation
• Agilent Technologies
• Takara Bio Inc
• Bio-Techne
• Bruker Corporation
• Shimadzu Corporation

11. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

12. Appendix

• List of Abbreviations
• Sources and References